Reviews/Alzheimers Disease Treatment/Memantine plus cholinesterase inhibitor beats monotherapy
Symptomatic · AD-SYM-03 · v2
The question is whether adding memantine on top of a cholinesterase inhibitor such as donepezil works better than either drug alone. Several analyses in people with moderate-to-severe Alzheimer's disease found that adding memantine to donepezil improved thinking and behaviour more than donepezil plus a dummy pill [22][24], and a pooled re-analysis of trial data argued the same [38]; large record-based studies also linked the combination to longer survival and fewer hospital visits [26][28]. But the one independent, government-funded trial that actually randomised patients to the combination versus donepezil alone found no clear extra benefit [1]. The supportive trials were run by the drug's maker, helped on some measures but not others, and the record-based studies cannot rule out that patients on the combination were simply different to begin with. The evidence genuinely points both ways, and the claim is also worded more broadly than what was tested, which is why the panel did not treat it as settled.
In moderate-to-severe Alzheimer's disease, adding extended-release memantine to a stable donepezil regimen beat donepezil-plus-placebo on cognition and behaviour but not on global status or daily function, with CIBIC-Plus P=0.165 and ADCS-ADL 19 P=0.894 in the prospective analysis [24], and a 24-week exploratory analysis showed behavioural benefit [22]. A pooled re-analysis concluded that adding memantine to donepezil is associated with benefits across multiple clinical domains [38]. Observational causal-inference studies of electronic health records linked the combination to higher five-year survival, by 0.065 (0.035, 0.095) versus donepezil monotherapy [26], and to fewer hospital or emergency visits [28]. A pharmacokinetic study found no interaction between the two drugs, supporting safe co-administration [30]. Against all of this, the independent factorial trial reported no significant benefits of the combination over donepezil alone [1]. The contested point: The evidence divides on the single direct test: [1], the only independent, publicly-funded factorial RCT randomising the combination against donepezil alone, found no significant combination benefit, while the supportive signal comes from sponsor-funded add-on-versus-placebo analyses [22][24][38] and confounding-prone observational data [26][28]. The claim's general wording also outruns an evidence base confined to moderate-to-severe disease on a donepezil background.
All 38 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alzheimers Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only independent, publicly-funded factorial RCT that randomised the exact comparison — combination versus donepezil alone — found no significant combination benefit on its co-primary cognitive and functional outcomes [1], directly contradicting the claim's wording.
The positive RCT analyses [22][24] are add-on memantine versus placebo on a donepezil background, are Forest Research Institute-sponsored, and show domain-selective effects: [24] found no prospective advantage on global status (CIBIC-Plus P=0.165) or daily function (ADCS-ADL 19 P=0.894), and [22] was a hypothesis-generating exploratory behavioural analysis.
Where it remains uncertain. The only independent factorial RCT directly randomising combination versus donepezil alone reported no significant benefit of the combination [1], and the positive trials were Forest-sponsored with effects on some domains but not CIBIC-Plus or ADCS-ADL 19 [24].
Aleatory
Within the same subset analysis, add-on memantine reached significance on SIB, NPI and VFT but not CIBIC-Plus (P=0.165) or ADCS-ADL 19 (P=0.894) [24], so benefit varies by measure and visit.
Epistemic
The survival and utilisation estimates [26][28] come from EHR analyses where patients on combination therapy may differ systematically (confounding-by-indication, healthy-adherer bias), so a causal reading is not established.
The load-bearing papers from a corpus of 38, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Memantine added to stable donepezil improved behavioural outcomes versus donepezil+placebo in moderate-to-severe AD
“Patients treated with memantine had significantly lower NPI total scores than patients treated with placebo.”
Panel auditInternal validity: medium · scope of inference: Behavioral symptoms in moderate-to-severe AD patients on stable donepezil.Key limitations: exploratory analysis · behavioral domain only · single ChEI
Add-on memantine to donepezil improved cognition/behaviour but not global/functional endpoints — partial, domain-selective support
“The prospective analyses revealed a significant endpoint advantage of MemER/Don over Placebo/Don on the SIB (P =0.001), NPI (P =0.009), and VFT (P<0.001), but not on the CIBIC-Plus (P =0.165) or ADCS-ADL 19 (P =0.894).”
Panel auditInternal validity: medium · scope of inference: Moderate-to-severe AD patients on stable donepezil.Key limitations: subset analysis · no functional benefit · sponsor-funded
Observational causal-inference evidence that combination beats each monotherapy on five-year survival
“their combined use increases the probability of five-year survival by 0.050 (0.021, 0.078) (6.4%), 0.049 (0.012, 0.085), (6.3%), 0.065 (0.035, 0.095) (8.3%) compared to no drug treatment, the Memantine monotherapy, and the Donepezil monotherapy respectively.”
Panel auditInternal validity: medium · scope of inference: AD patients in a large EHR database, survival outcome.Key limitations: observational · confounding by indication · survival not symptom outcome
Direct factorial-RCT test of the claim; refutes combination superiority over ChEI monotherapy on co-primary cognitive/functional outcomes
“There were no significant benefits of the combination of donepezil and memantine over donepezil alone.”
Panel auditInternal validity: high · scope of inference: Community-dwelling patients with moderate or severe AD already on donepezil.Key limitations: single ChEI (donepezil) only · moderate-severe stage only
4 of 38 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus genuinely conflicts — selective RCT and confounded observational support for combination in moderate-to-severe AD is offset by a negative independent factorial RCT and a claim broader than the evidence, placing confidence in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent head-to-head combination versus monotherapy trial. The only direct independent randomisation [1] is negative and the supportive trials are add-on-versus-placebo and sponsor-funded [22][24], so the claim's core comparison lacks confirmatory independent evidence. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A publicly-funded, adequately powered RCT randomising memantine-plus-ChEI against ChEI monotherapy (and memantine monotherapy), with cognition, behaviour, global status and daily function as co-primary endpoints.
Open question: Does adding memantine to a cholinesterase inhibitor improve global status and daily function, not only cognition and behaviour, over monotherapy? Why it is still open: The supportive subset analysis showed benefit on SIB, NPI and VFT but not CIBIC-Plus (P=0.165) or ADCS-ADL 19 (P=0.894) [24], and the independent factorial RCT found no combination benefit on its co-primary outcomes [1].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19